WHEN it comes to issues of obesity, there is no doubt that so-called fat jabs have turned the tide on treatment options. Even ...

Stigma and misunderstanding of obesity are preventing people from receiving adequate treatment for the disease, which is ...

Novo Nordisk's new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Discover how popular GLP-1 weight loss medications like Ozempic may trigger eating disorder relapse in vulnerable users and ...

Obesity has long been one of America's most persistent and complex public health challenges. Despite the rise and fall of countless weight-loss fads and miracle diets, millions of people still find ...

A popular pharmaceutical intervention for weight loss may also have the potential to curb alcoholism, as researchers observed a “commonality of function.” Between those who swear by […] ...

A new study suggests that weight-loss drugs may significantly reduce alcohol consumption in people with obesity.

Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...

An alarming number of bariatric surgeons are considering shutting their clinics because of skyrocketing insurance costs and ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

Discover how semaglutide reduces heart attack and stroke risk by 20% in overweight individuals, with benefits appearing ...